Breath Of Fresh Air For Cystic Fibrosis Drug Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The outlook for cystic fibrosis drug development now is "a very different story than even five years ago," according to Cystic Fibrosis Foundation President Robert Beall.
You may also be interested in...
Cystic Fibrosis Market Snapshot: Disease-Modifying Drugs Elusive 24 Years After Discovery Of Root Cause
The discovery in 1989 of the underlying genetics causing cystic fibrosis was expected to spur broad development of disease-modifying therapies. As of 2013, however, only one such drug is on the market, for a small subset of CF patients, and a few other candidates are in clinical development.
Vertex Offers Cystic Fibrosis Patients A Chance To Breathe Easier
While most attention has been on Vertex Pharmaceuticals' hepatitis C drug telaprevir, which is widely expected to gain FDA approval in May, the company has also been steadily progressing on its investigational cystic fibrosis agents, and it may have lined up another home run.
Vertex Offers Cystic Fibrosis Patients A Chance To Breathe Easier
While most attention has been on Vertex Pharmaceuticals' hepatitis C drug telaprevir, which is widely expected to gain FDA approval in May, the company has also been steadily progressing on its investigational cystic fibrosis agents, and it may have lined up another home run.